96 related articles for article (PubMed ID: 22098064)
21. Looking to the future: new agents for chronic hepatitis B.
Dienstag JL
Am J Gastroenterol; 2006; 101 Suppl 1():S19-25. PubMed ID: 16448448
[TBL] [Abstract][Full Text] [Related]
22. Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir? Authors' reply.
Gao L; Trinh HN; Li J; Nguyen MH
Aliment Pharmacol Ther; 2014 Jun; 39(11):1339-40. PubMed ID: 24803254
[No Abstract] [Full Text] [Related]
23. Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients--authors' reply.
Gao L; Trinh HN; Li J; Nguyen MH
Aliment Pharmacol Ther; 2014 May; 39(9):993. PubMed ID: 24689344
[No Abstract] [Full Text] [Related]
24. [Long-term entecavir efficacy retention in the treatment of chronic hepatitis B with an outcome to hepatic cirrhosis caused by its resistant virus strain].
Znoiko OO; Dudina KR; Safiullina NKh; Karandashova IV; Chulanov VP
Ter Arkh; 2012; 84(11):61-3. PubMed ID: 23252250
[TBL] [Abstract][Full Text] [Related]
25. Chronic hepatitis B infection in pregnancy illustrated by a case of successful treatment with entecavir.
Kakogawa J; Sakurabashi A; Sadatsuki M; Gomibuchi H; Minoura S
Arch Gynecol Obstet; 2011 Dec; 284(6):1595-6. PubMed ID: 21861151
[No Abstract] [Full Text] [Related]
26. Five-year data released for entecavir.
AIDS Patient Care STDS; 2008 Apr; 22(4):349. PubMed ID: 18422464
[No Abstract] [Full Text] [Related]
27. Identification of hepatitis B virus DNA reverse transcriptase variants associated with partial response to entecavir.
Wong DK; Fung J; Lai CL; Yuen MF
Hong Kong Med J; 2015 Jun; 21 Suppl 4():35-8. PubMed ID: 26157102
[No Abstract] [Full Text] [Related]
28. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis.
Kishida D; Okuda Y; Onishi M; Takebayashi M; Matoba K; Jouyama K; Yamada A; Sawada N; Mokuda S; Takasugi K
Mod Rheumatol; 2011 Apr; 21(2):215-8. PubMed ID: 20931272
[TBL] [Abstract][Full Text] [Related]
29. Liver disease progression and virological response: entecavir rescue still possible in the setting of rtM204I lamivudine-resistant mutation.
Tan PS; Aung MO; Dan YY; Lee YM; Lim K; Low HC; Lee GH; Thwin MA; Soon C; Lim SG
Gut; 2013 May; 62(5):801-2. PubMed ID: 23144055
[No Abstract] [Full Text] [Related]
30. Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade.
Yim HJ; Hwang SG
Clin Mol Hepatol; 2013 Sep; 19(3):195-209. PubMed ID: 24133659
[TBL] [Abstract][Full Text] [Related]
31. [Emergence of entecavir genotypic resistance in a nucleoside naive chronic hepatitis B patient who had been treated for nearly five years: a case report].
Liu F; Wang XW
Zhonghua Gan Zang Bing Za Zhi; 2013 Oct; 21(10):781-2. PubMed ID: 24579214
[No Abstract] [Full Text] [Related]
32. Entecavir (Baraclude°) and chronic hepatitis B in children.
Prescrire Int; 2017 Feb; 26(179):42-43. PubMed ID: 30726630
[No Abstract] [Full Text] [Related]
33. Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy.
Pillai AA; Anania FA; Pearlman BL
Am J Gastroenterol; 2016 Dec; 111(12):1854-1856. PubMed ID: 27924099
[No Abstract] [Full Text] [Related]
34. Successful Treatment of Hepatitis B Virus-associated Membranous Nephropathy with Entecavir and Immunosuppressive Agents.
Ochi A; Ishimura E; Ichii M; Ohno Y; Nakatani S; Kobayashi I; Shima H; Tsuda A; Shidara K; Mori K; Tamori A; Inaba M
Nephrology (Carlton); 2014 Sep; 19(9):595-6. PubMed ID: 25156438
[No Abstract] [Full Text] [Related]
35. [Efficacy of entecavir treatment in hepatitis B virus-related decompensated cirrhosis].
Kim YS
Korean J Gastroenterol; 2012 Mar; 59(3):203-4. PubMed ID: 22563614
[No Abstract] [Full Text] [Related]
36. [Chronic hepatitis B, advances in treatment].
Buffet C
Presse Med; 2006 Feb; 35(2 Pt 2):302-3. PubMed ID: 16493333
[No Abstract] [Full Text] [Related]
37. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.
Zoulim F; Trépo C
J Hepatol; 1998 Jul; 29(1):151-68. PubMed ID: 9696505
[No Abstract] [Full Text] [Related]
38. Management of antiviral drug resistance in chronic hepatitis B.
Bang KB; Kim HJ
World J Gastroenterol; 2014 Sep; 20(33):11641-9. PubMed ID: 25206270
[TBL] [Abstract][Full Text] [Related]
39. Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B?
Kim JH; Lee JS
Korean J Intern Med; 2015 Jan; 30(1):23-6. PubMed ID: 25589830
[No Abstract] [Full Text] [Related]
40. Who will have the best response to entecavir?
Wong GL
J Gastroenterol Hepatol; 2013 Jan; 28(1):5-7. PubMed ID: 23278152
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
